Skip to content
Screener

AnaptysBio, Inc. ANAB Net Change in Cash

Net Change in Cash at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$861M-150%
Eli Lilly logo
Eli LillyLLY
$3.67B+1,196%
Pfizer logo
PfizerPFE
$563M+50.1%
Amgen logo
AmgenAMGN
$1.95B+349%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$504.6M+53.2%
Biogen logo
BiogenBIIB
-$2.09B-2,371%

Other financials

Income statement

See full
Revenue$25.6M-8.0%
Operating income-$34.6M-25.8%
Net income-$52.9M-34.5%
EPS (diluted)-$1.84-43.8%

Balance sheet

See full
Cash & equivalents$248.5M+152%
Total debt$13.6K-99.9%
Total equity$12.7M-62.5%
Total assets$329.7M-21.9%

Cash flow

See full
Operating cash flow-$25.9M-142%
CapEx$17.0K-51.4%
Free cash flow-$25.9M-142%

Valuation

See full
Market cap$1.62B+145%
Enterprise value$1.37B+117%
P/S+1.6×

Profitability

See full
Operating margin17.6%+9.6pp
Net margin-49.9%-22.6pp
FCF margin1.9%+1.0pp

Returns & leverage

See full
Return on equity-343.8%-1,012pp
Debt / equity-0.5×
Current ratio7.6×-0.7×

Where this comes from

Reported directly by AnaptysBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The source filing: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:20 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-219515
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Payment for net share settlement of equity awards(1,451)
Principal repayment of liability for sale of future royalties(12,812)(23,005)
Net cash provided by (used in) financing activities1,209(28,590)
Net increase (decrease) in cash and cash equivalents10,273(24,443)
Cash and cash equivalents, beginning of period238,196123,080
Cash and cash equivalents, end of period$248,469$98,637
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Interest portion of repayment for sale of future royalties$20,833$18,100

Item 1. Consolidated Financial Statements

FAQ

What is AnaptysBio, Inc.'s net change in cash?
AnaptysBio, Inc. (ANAB) reported net change in cash of $10.27M in Q1 2026.
How has AnaptysBio, Inc.'s net change in cash changed year-over-year?
AnaptysBio, Inc.'s net change in cash increased by 142.0% year-over-year, from -$24.44M to $10.27M.
What is the long-term trend for AnaptysBio, Inc.'s net change in cash?
Over 2 years (2021 to 2025), AnaptysBio, Inc.'s net change in cash has grown at a -31.5% compound annual growth rate (CAGR), from $245.21M to $115.12M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about AnaptysBio, Inc.'s net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude